stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Free cash flow
Erasca, Inc.'s free cash flow for fiscal 2025 was −$105.1M, compared with −$132.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$252.1M. Over the past ten years it has ranged from −$132.0M (fiscal 2024) to −$10.4M (fiscal 2019); the current reading is higher than 57% of that period. Erasca, Inc. ranks 559th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$105.1M | — |
| FY2024 | −$132.0M | — |
| FY2023 | −$123.0M | — |
| FY2022 | −$119.8M | — |
| FY2021 | −$98.5M | — |
| FY2020 | −$71.4M | — |
| FY2019 | −$10.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$27.3M | — |
| Mar 2026 | −$177.4M | — |
| Dec 2025 | −$21.7M | — |
| Sep 2025 | −$25.7M | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$132.0M
High −$10.4M
Ten-year median
−$105.1M
Current reading's percentile
57
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $85.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$121.8M |
| MANE Veradermics Incorporated compare | −$123.0M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$202.3M |
| ERAS Erasca, Inc. | −$252.1M |
| COGT Cogent Biosciences, Inc. compare | −$309.2M |
| CRSP CRISPR Therapeutics AG compare | −$376.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)